Tony Velkov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2402963/publications.pdf

Version: 2024-02-01

220 papers

8,255 citations

44069 48 h-index 71685 **76** g-index

221 all docs

221 docs citations

times ranked

221

8608 citing authors

#	Article	lF	CITATIONS
1	Interactions between polymyxin B and various bacterial membrane mimics: A molecular dynamics study. Colloids and Surfaces B: Biointerfaces, 2022, 211, 112288.	5.0	6
2	Comparative metabolomics revealed key pathways associated with the synergistic killing of multidrug-resistant Klebsiella pneumoniae by a bacteriophage-polymyxin combination. Computational and Structural Biotechnology Journal, 2022, 20, 485-495.	4.1	12
3	Polymyxin causes cell envelope remodelling and stress responses in mcr-1-harbouring Escherichia coli. International Journal of Antimicrobial Agents, 2022, 59, 106505.	2.5	1
4	Unique mechanistic insights into pathways associated with the synergistic activity of polymyxin B and caspofungin against multidrug-resistant Klebsiella pneumoniae. Computational and Structural Biotechnology Journal, 2022, 20, 1077-1087.	4.1	10
5	The Natural Product Curcumin as an Antibacterial Agent: Current Achievements and Problems. Antioxidants, 2022, 11, 459.	5.1	55
6	Polymyxin Induces Significant Transcriptomic Perturbations of Cellular Signalling Networks in Human Lung Epithelial Cells. Antibiotics, 2022, 11 , 307.	3.7	0
7	p21 restricts influenza A virus by perturbing the viral polymerase complex and upregulating type I interferon signaling. PLoS Pathogens, 2022, 18, e1010295.	4.7	12
8	An Efficient Approach for the Design and Synthesis of Antimicrobial Peptide-Peptide Nucleic Acid Conjugates. Frontiers in Chemistry, 2022, 10, 843163.	3.6	9
9	Intraventricular Drug Delivery and Sampling for Pharmacokinetics and Pharmacodynamics Study. Journal of Visualized Experiments, 2022, , .	0.3	2
10	A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens. Nature Communications, 2022, 13, 1625.	12.8	53
11	Correlative proteomics identify the key roles of stress tolerance strategies in Acinetobacter baumannii in response to polymyxin and human macrophages. PLoS Pathogens, 2022, 18, e1010308.	4.7	6
12	Polymyxin dose tunes the evolutionary dynamics of resistance in multidrug-resistant Acinetobacter baumannii. Clinical Microbiology and Infection, 2022, 28, 1026.e1-1026.e5.	6.0	4
13	Mechanisms Underlying Synergistic Killing of Polymyxin B in Combination with Cannabidiol against Acinetobacter baumannii: A Metabolomic Study. Pharmaceutics, 2022, 14, 786.	4.5	11
14	Colistin-induced pulmonary toxicity involves the activation of NOX4/TGF- \hat{l}^2 /mtROS pathway and the inhibition of Akt/mTOR pathway. Food and Chemical Toxicology, 2022, 163, 112966.	3.6	6
15	Inwardly rectifying potassium channels mediate polymyxin-induced nephrotoxicity. Cellular and Molecular Life Sciences, 2022, 79, 296.	5.4	4
16	An Intelligent Strategy with All-Atom Molecular Dynamics Simulations for the Design of Lipopeptides against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> . Journal of Medicinal Chemistry, 2022, 65, 10001-10013.	6.4	6
17	T-2 toxin and its cardiotoxicity: New insights on the molecular mechanisms and therapeutic implications. Food and Chemical Toxicology, 2022, 167, 113262.	3.6	11
18	DNA variants are an unlikely explanation for the changing quality of spermatozoa within the same individual. Human Fertility, 2021, 24, 376-388.	1.7	0

#	Article	IF	CITATIONS
19	Comparative metabolomics reveals key pathways associated with the synergistic activity of polymyxin B and rifampicin combination against multidrug-resistant Acinetobacter baumannii. Biochemical Pharmacology, 2021, 184, 114400.	4.4	16
20	Rescuing the Last-Line Polymyxins: Achievements and Challenges. Pharmacological Reviews, 2021, 73, 679-728.	16.0	167
21	Evaluation Strategies for Tripleâ€Drug Combinations against Carbapenemaseâ€Producing <i>Klebsiella Pneumoniae</i> in an <i>In Vitro</i> Hollowâ€Fiber Infection Model. Clinical Pharmacology and Therapeutics, 2021, 109, 1074-1080.	4.7	10
22	In vitro evaluation of drug delivery behavior for inhalable amorphous nanoparticle formulations in a human lung epithelial cell model. International Journal of Pharmaceutics, 2021, 596, 120211.	5.2	7
23	Synergy of the Polymyxin-Chloramphenicol Combination against New Delhi Metallo- \hat{l}^2 -Lactamase-Producing <i>Klebsiella pneumoniae</i> Is Predominately Driven by Chloramphenicol. ACS Infectious Diseases, 2021, 7, 1584-1595.	3.8	14
24	Clinically Relevant Concentrations of Polymyxin B and Meropenem Synergistically Kill Multidrug-Resistant Pseudomonas aeruginosa and Minimize Biofilm Formation. Antibiotics, 2021, 10, 405.	3.7	7
25	Synchrotron-Based X-Ray Fluorescence Microscopy Reveals Accumulation of Polymyxins in Single Human Alveolar Epithelial Cells. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	5
26	Inhibition of Oxidative Stress and ALOX12 and NF-κB Pathways Contribute to the Protective Effect of Baicalein on Carbon Tetrachloride-Induced Acute Liver Injury. Antioxidants, 2021, 10, 976.	5.1	55
27	Polymyxins for the treatment of lower respiratory tract infections: lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomes. International Journal of Antimicrobial Agents, 2021, 57, 106328.	2.5	11
28	A Precision Medicine Approach to Optimize Modulator Therapy for Rare CFTR Folding Mutants. Journal of Personalized Medicine, 2021, 11, 643.	2.5	20
29	Polymyxin-Induced Metabolic Perturbations in Human Lung Epithelial Cells. Antimicrobial Agents and Chemotherapy, 2021, 65, e0083521.	3.2	3
30	Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis. Frontiers in Pharmacology, 2021, 12, 577263.	3.5	6
31	Coarse-grained simulations uncover Gram-negative bacterial defense against polymyxins by the outer membrane. Computational and Structural Biotechnology Journal, 2021, 19, 3885-3891.	4.1	13
32	A novel chemical biology and computational approach to expedite the discovery of new-generation polymyxins against life-threatening <i>Acinetobacter baumannii</i> . Chemical Science, 2021, 12, 12211-12220.	7.4	13
33	Antimicrobial Peptides: An Update on Classifications and Databases. International Journal of Molecular Sciences, 2021, 22, 11691.	4.1	106
34	Biophysical Impact of Lipid A Modification Caused by Mobile Colistin Resistance Gene on Bacterial Outer Membranes. Journal of Physical Chemistry Letters, 2021, 12, 11629-11635.	4.6	9
35	Mass Spectrometry Reveals New Insights into the Production of Superoxide Anions and 4â€Hydroxynonenal Adducted Proteins in Human Sperm. Proteomics, 2020, 20, e1900205.	2.2	10
36	Inhalable liposomal powder formulations for co-delivery of synergistic ciprofloxacin and colistin against multi-drug resistant gram-negative lung infections. International Journal of Pharmaceutics, 2020, 575, 118915.	5.2	43

#	Article	IF	CITATIONS
37	Synthesis and structureâ^activity relationships of teixobactin. Annals of the New York Academy of Sciences, 2020, 1459, 86-105.	3.8	26
38	Polymyxin B combinations with FDA-approved non-antibiotic phenothiazine drugs targeting multi-drug resistance of Gram-negative pathogens. Computational and Structural Biotechnology Journal, 2020, 18, 2247-2258.	4.1	17
39	Structure–Activity Relationships of Daptomycin Lipopeptides. Journal of Medicinal Chemistry, 2020, 63, 13266-13290.	6.4	30
40	Polymyxin-Induced Cell Death of Human Macrophage-Like THP-1 and Neutrophil-Like HL-60 Cells Associated with the Activation of Apoptotic Pathways. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	5
41	The Antimicrobial Activity of Cannabinoids. Antibiotics, 2020, 9, 406.	3.7	64
42	Genome-Scale Metabolic Modeling Reveals Metabolic Alterations of Multidrug-Resistant Acinetobacter baumannii in a Murine Bloodstream Infection Model. Microorganisms, 2020, 8, 1793.	3.6	12
43	Lipid A profiling and metabolomics analysis of paired polymyxin-susceptible and -resistant MDR <i>Klebsiella pneumoniae</i> clinical isolates from the same patients before and after colistin treatment. Journal of Antimicrobial Chemotherapy, 2020, 75, 2852-2863.	3.0	14
44	Outer Membranes of Polymyxin-Resistant <i>Acinetobacter baumannii</i> with Phosphoethanolamine-Modified Lipid A and Lipopolysaccharide Loss Display Different Atomic-Scale Interactions with Polymyxins. ACS Infectious Diseases, 2020, 6, 2698-2708.	3.8	19
45	Simulations of octapeptin–outer membrane interactions reveal conformational flexibility is linked to antimicrobial potency. Journal of Biological Chemistry, 2020, 295, 15902-15912.	3.4	13
46	Sialylation of Asparagine 612 Inhibits Aconitase Activity during Mouse Sperm Capacitation; a Possible Mechanism for the Switch from Oxidative Phosphorylation to Glycolysis. Molecular and Cellular Proteomics, 2020, 19, 1860-1875.	3.8	4
47	Molecular dynamics simulations informed by membrane lipidomics reveal the structure–interaction relationship of polymyxins with the lipid A-based outer membrane of <i>Acinetobacter baumannii</i> Journal of Antimicrobial Chemotherapy, 2020, 75, 3534-3543.	3.0	25
48	Nerve Growth Factor Confers Neuroprotection against Colistin-Induced Peripheral Neurotoxicity. ACS Infectious Diseases, 2020, 6, 1451-1459.	3.8	7
49	Polymyxin Triple Combinations against Polymyxin-Resistant, Multidrug-Resistant, KPC-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	13
50	Effective Strategy Targeting Polymyxin-Resistant Gram-Negative Pathogens: Polymyxin B in Combination with the Selective Serotonin Reuptake Inhibitor Sertraline. ACS Infectious Diseases, 2020, 6, 1436-1450.	3.8	20
51	The Killing Mechanism of Teixobactin against Methicillin-Resistant Staphylococcus aureus: an Untargeted Metabolomics Study. MSystems, 2020, 5, .	3.8	33
52	Polymyxins–Curcumin Combination Antimicrobial Therapy: Safety Implications and Efficacy for Infection Treatment. Antioxidants, 2020, 9, 506.	5.1	26
53	Transcriptomic responses of a New Delhi metallo- \hat{l}^2 -lactamase-producing Klebsiella pneumoniae isolate to the combination of polymyxin B and chloramphenicol. International Journal of Antimicrobial Agents, 2020, 56, 106061.	2.5	10
54	Polymyxins Bind to the Cell Surface of Unculturable <i>Acinetobacter baumannii</i> and Cause Unique Dependent Resistance. Advanced Science, 2020, 7, 2000704.	11.2	31

#	Article	IF	CITATIONS
55	Structure–Interaction Relationship of Polymyxins with the Membrane of Human Kidney Proximal Tubular Cells. ACS Infectious Diseases, 2020, 6, 2110-2119.	3.8	18
56	Complete genome sequence and genome-scale metabolic modelling of Acinetobacter baumannii type strain ATCC 19606. International Journal of Medical Microbiology, 2020, 310, 151412.	3.6	11
57	Curcumin Attenuates Colistin-Induced Peripheral Neurotoxicity in Mice. ACS Infectious Diseases, 2020, 6, 715-724.	3.8	29
58	Structure of micelle bound cationic peptides by NMR spectroscopy using a lanthanide shift reagent. Chemical Communications, 2020, 56, 2897-2900.	4.1	6
59	Regulating polymyxin resistance in Gram-negative bacteria: roles of two-component systems PhoPQ and PmrAB. Future Microbiology, 2020, 15, 445-459.	2.0	51
60	Pan-transcriptomic analysis identified common differentially expressed genes of <i>Acinetobacter baumannii </i> i>in response to polymyxin treatments. Molecular Omics, 2020, 16, 327-338.	2.8	7
61	Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination. JCI Insight, 2020, 5, .	5.0	159
62	Intracellular localization of polymyxins in human alveolar epithelial cells. Journal of Antimicrobial Chemotherapy, 2019, 74, 48-57.	3.0	11
63	The impact of backbone N â€methylation on the structureâ€activity relationship of Leu 10 â€teixobactin. Journal of Peptide Science, 2019, 25, e3206.	1.4	6
64	Polymyxin resistance in Klebsiella pneumoniae: multifaceted mechanisms utilized in the presence and absence of the plasmid-encoded phosphoethanolamine transferase gene mcr-1. Journal of Antimicrobial Chemotherapy, 2019, 74, 3190-3198.	3.0	12
65	Multifaceted mechanisms of colistin resistance revealed by genomic analysis of multidrug-resistant Klebsiella pneumoniae isolates from individual patients before and after colistin treatment. Journal of Infection, 2019, 79, 312-321.	3.3	24
66	Comparative Metabolomics Reveals Key Pathways Associated With the Synergistic Killing of Colistin and Sulbactam Combination Against Multidrug-Resistant Acinetobacter baumannii. Frontiers in Pharmacology, 2019, 10, 754.	3.5	21
67	Mechanisms of Polymyxin-Induced Nephrotoxicity. Advances in Experimental Medicine and Biology, 2019, 1145, 305-319.	1.6	26
68	History, Chemistry and Antibacterial Spectrum. Advances in Experimental Medicine and Biology, 2019, 1145, 15-36.	1.6	22
69	Discovery of Novel Polymyxin-Like Antibiotics. Advances in Experimental Medicine and Biology, 2019, 1145, 343-362.	1.6	16
70	Polymyxins: Mode of Action. Advances in Experimental Medicine and Biology, 2019, 1145, 37-54.	1.6	35
71	Synergistic Combination of Polymyxin B and Enrofloxacin Induced Metabolic Perturbations in Extensive Drug-Resistant Pseudomonas aeruginosa. Frontiers in Pharmacology, 2019, 10, 1146.	3.5	17
72	Metabolomics Study of the Synergistic Killing of Polymyxin B in Combination with Amikacin against Polymyxin-Susceptible and -Resistant Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2019, 64, .	3.2	28

#	Article	IF	CITATIONS
73	T-2 toxin neurotoxicity: role of oxidative stress and mitochondrial dysfunction. Archives of Toxicology, 2019, 93, 3041-3056.	4.2	89
74	Novel Polymyxin Combination with the Antiretroviral Zidovudine Exerts Synergistic Killing against NDM-Producing Multidrug-Resistant Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	16
75	The rise and spread of i>mcrplasmid-mediated polymyxin resistance. Critical Reviews in Microbiology, 2019, 45, 131-161.	6.1	174
76	Global Metabolic Analyses of Acinetobacter baumannii. Methods in Molecular Biology, 2019, 1946, 321-328.	0.9	2
77	Effects of the antibiotic component on in-vitro bacterial killing, physico-chemical properties, aerosolization and dissolution of a ternary-combinational inhalation powder formulation of antibiotics for pan-drug resistant Gram-negative lung infections. International Journal of Pharmaceutics. 2019. 561. 102-113.	5.2	11
78	Metabolic Responses to Polymyxin Treatment in <i>Acinetobacter baumannii</i> Integrating Transcriptomics and Metabolomics with Genome-Scale Metabolic Modeling. MSystems, 2019, 4, .	3.8	28
79	An optimised Cu(0)-RDRP approach for the synthesis of lipidated oligomeric vinyl azlactone: toward a versatile antimicrobial materials screening platform. Journal of Materials Chemistry B, 2019, 7, 6796-6809.	5.8	11
80	Comparative Metabolomics and Transcriptomics Reveal Multiple Pathways Associated with Polymyxin Killing in Pseudomonas aeruginosa. MSystems, 2019, 4, .	3.8	52
81	Molecular Mechanisms of Neurotoxicity Induced by Polymyxins and Chemoprevention. ACS Chemical Neuroscience, 2019, 10, 120-131.	3.5	45
82	Contemporary Anti-Ebola Drug Discovery Approaches and Platforms. ACS Infectious Diseases, 2019, 5, 35-48.	3.8	3
83	Fitness cost of mcr-1-mediated polymyxin resistance in Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 2018, 73, 1604-1610.	3.0	68
84	Polymyxin B in Combination with Enrofloxacin Exerts Synergistic Killing against Extensively Drug-Resistant Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	15
85	Alterations of Metabolic and Lipid Profiles in Polymyxin-Resistant Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	58
86	T-2 toxin-induced toxicity in neuroblastoma-2a cells involves the generation of reactive oxygen, mitochondrial dysfunction and inhibition of Nrf2/HO-1 pathway. Food and Chemical Toxicology, 2018, 114, 88-97.	3.6	49
87	Structure, Function, and Biosynthetic Origin of Octapeptin Antibiotics Active against Extensively Drug-Resistant Gram-Negative Bacteria. Cell Chemical Biology, 2018, 25, 380-391.e5.	5.2	57
88	A Proof-of-Concept Study of the Efficacy of Systemically Administered Polymyxins in Mouse Burn Wound Infection Caused by Multidrug-Resistant Gram-Negative Pathogens. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	2
89	Comparative analysis of phosphoethanolamine transferases involved in polymyxin resistance across 10 clinically relevant Gram-negative bacteria. International Journal of Antimicrobial Agents, 2018, 51, 586-593.	2.5	18
90	Rapamycin Confers Neuroprotection against Colistin-Induced Oxidative Stress, Mitochondria Dysfunction, and Apoptosis through the Activation of Autophagy and mTOR/Akt/CREB Signaling Pathways. ACS Chemical Neuroscience, 2018, 9, 824-837.	3.5	67

#	Article	IF	Citations
91	The inhibitory effects of eighteen front-line antibiotics on the substrate uptake mediated by human Organic anion/cation transporters, Organic anion transporting polypeptides and Oligopeptide transporters in in vitro models. European Journal of Pharmaceutical Sciences, 2018, 115, 132-143.	4.0	10
92	Proteomic analysis of good- and poor-quality human sperm demonstrates that several proteins are routinely aberrantly regulated. Biology of Reproduction, 2018, 99, 395-408.	2.7	44
93	The potentially beneficial central nervous system activity profile of ivacaftor and its metabolites. ERJ Open Research, 2018, 4, 00127-2017.	2.6	21
94	Sputum Active Polymyxin Lipopeptides: Activity against Cystic FibrosisPseudomonas aeruginosalsolates and Their Interactions with Sputum Biomolecules. ACS Infectious Diseases, 2018, 4, 646-655.	3.8	19
95	Genome-scale metabolic modeling of responses to polymyxins in <i>Pseudomonas aeruginosa</i> GigaScience, 2018, 7, .	6.4	44
96	Curcumin Attenuates Colistin-Induced Neurotoxicity in N2a Cells via Anti-inflammatory Activity, Suppression of Oxidative Stress, and Apoptosis. Molecular Neurobiology, 2018, 55, 421-434.	4.0	78
97	Polymyxins for CNS infections: Pharmacology and neurotoxicity. , 2018, 181, 85-90.		71
98	Broad activity of diphenyleneiodonium analogues against Mycobacterium tuberculosis, malaria parasites and bacterial pathogens. European Journal of Medicinal Chemistry, 2018, 148, 507-518.	5.5	14
99	Methionine Ameliorates Polymyxin-Induced Nephrotoxicity by Attenuating Cellular Oxidative Stress. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	20
100	Polymyxin-Induced Lipid A Deacylation in <i>Pseudomonas aeruginosa</i> Perturbs Polymyxin Penetration and Confers High-Level Resistance. ACS Chemical Biology, 2018, 13, 121-130.	3.4	59
101	Metabolic Analyses Revealed Time-Dependent Synergistic Killing by Colistin and Aztreonam Combination Against Multidrug-Resistant Acinetobacter baumannii. Frontiers in Microbiology, 2018, 9, 2776.	3.5	20
102	Chloroquine ameliorates carbon tetrachloride-induced acute liver injury in mice via the concomitant inhibition of inflammation and induction of apoptosis. Cell Death and Disease, 2018, 9, 1164.	6.3	115
103	Mechanistic Insights From Global Metabolomics Studies into Synergistic Bactericidal Effect of a Polymyxin B Combination With Tamoxifen Against Cystic Fibrosis MDR Pseudomonas aeruginosa. Computational and Structural Biotechnology Journal, 2018, 16, 587-599.	4.1	19
104	Exploiting Macromolecular Design To Optimize the Antibacterial Activity of Alkylated Cationic Oligomers. Biomacromolecules, 2018, 19, 4629-4640.	5.4	14
105	A Comparative Study of Outer Membrane Proteome between Paired Colistin-Susceptible and Extremely Colistin-Resistant <i>Klebsiella pneumoniae</i>	3.8	15
106	Grapheneâ€Enhanced 3D Chemical Mapping of Biological Specimens at Nearâ€Atomic Resolution. Advanced Functional Materials, 2018, 28, 1801439.	14.9	14
107	Composite particle formulations of colistin and meropenem with improved in-vitro bacterial killing and aerosolization for inhalation. International Journal of Pharmaceutics, 2018, 548, 443-453.	5.2	20
108	Synergistic Killing of Polymyxin B in Combination With the Antineoplastic Drug Mitotane Against Polymyxin-Susceptible and -Resistant Acinetobacter baumannii: A Metabolomic Study. Frontiers in Pharmacology, 2018, 9, 359.	3.5	14

#	Article	IF	CITATIONS
109	Novel Polymyxin Combination With Antineoplastic Mitotane Improved the Bacterial Killing Against Polymyxin-Resistant Multidrug-Resistant Gram-Negative Pathogens. Frontiers in Microbiology, 2018, 9, 721.	3.5	34
110	Lipidomic Analysis of the Outer Membrane Vesicles from Paired Polymyxin-Susceptible and -Resistant Klebsiella pneumoniae Clinical Isolates. International Journal of Molecular Sciences, 2018, 19, 2356.	4.1	23
111	Functional Characterization of the Unique Terminal Thioesterase Domain from Polymyxin Synthetase. Biochemistry, 2017, 56, 657-668.	2.5	8
112	Plasma Protein Binding Structure–Activity Relationships Related to the N-Terminus of Daptomycin. ACS Infectious Diseases, 2017, 3, 249-258.	3.8	20
113	Pharmacokinetics of the Individual Major Components of Polymyxin B and Colistin in Rats. Journal of Natural Products, 2017, 80, 225-229.	3.0	26
114	A traceless reversible polymeric colistin prodrug to combat multidrug-resistant (MDR) gram-negative bacteria. Journal of Controlled Release, 2017, 259, 83-91.	9.9	15
115	Rediscovering the octapeptins. Natural Product Reports, 2017, 34, 295-309.	10.3	34
116	Potential Toxicity of Polymyxins in Human Lung Epithelial Cells. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	34
117	Characterization of the Polymyxin D Synthetase Biosynthetic Cluster and Product Profile of <i>Paenibacillus polymyxa</i> ATCC 10401. Journal of Natural Products, 2017, 80, 1264-1274.	3.0	27
118	Pulsed-voltage atom probe tomography of low conductivity and insulator materials by application of ultrathin metallic coating on nanoscale specimen geometry. Ultramicroscopy, 2017, 181, 150-159.	1.9	9
119	Minocycline attenuates colistin-induced neurotoxicity via suppression of apoptosis, mitochondrial dysfunction and oxidative stress. Journal of Antimicrobial Chemotherapy, 2017, 72, 1635-1645.	3.0	46
120	Untargeted metabolomics analysis reveals key pathways responsible for the synergistic killing of colistin and doripenem combination against Acinetobacter baumannii. Scientific Reports, 2017, 7, 45527.	3.3	89
121	From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs―Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators. Microbial Drug Resistance, 2017, 23, 640-650.	2.0	45
122	Cationic acrylate oligomers comprising amino acid mimic moieties demonstrate improved antibacterial killing efficiency. Journal of Materials Chemistry B, 2017, 5, 531-536.	5.8	38
123	Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	31
124	Gelofusine Ameliorates Colistin-Induced Nephrotoxicity. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	18
125	The first total synthesis and solution structure of a polypeptin, PE2, a cyclic lipopeptide with broad spectrum antibiotic activity. Organic and Biomolecular Chemistry, 2017, 15, 7173-7180.	2.8	5
126	Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients. Journal of Visualized Experiments, 2017, , .	0.3	11

#	Article	IF	Citations
127	Investigating the Interaction of Octapeptin A3 with Model Bacterial Membranes. ACS Infectious Diseases, 2017, 3, 606-619.	3.8	25
128	Baicalein acts as a nephroprotectant that ameliorates colistin-induced nephrotoxicity by activating the antioxidant defence mechanism of the kidneys and down-regulating the inflammatory response. Journal of Antimicrobial Chemotherapy, 2017, 72, 2562-2569.	3.0	51
129	Hydrolyzable Poly[Poly(Ethylene Glycol) Methyl Ether Acrylate]–Colistin Prodrugs through Copper-Mediated Photoinduced Living Radical Polymerization. Bioconjugate Chemistry, 2017, 28, 1916-1924.	3.6	11
130	A Hydrogelâ€Based Localized Release of Colistin for Antimicrobial Treatment of Burn Wound Infection. Macromolecular Bioscience, 2017, 17, 1600320.	4.1	51
131	A Fresh Shine on Cystic Fibrosis Inhalation Therapy: Antimicrobial Synergy of Polymyxin B in Combination with Silver Nanoparticles. Journal of Biomedical Nanotechnology, 2017, 13, 447-457.	1.1	12
132	Novel Antimicrobial Peptides: Targeting Wound Infections Caused by â€~Superbugs' Resistant to All Current Antibiotics. Recent Clinical Techniques, Results, and Research in Wounds, 2017, , 203-211.	0.1	0
133	Antibiotic–non-antibiotic combinations for combating extremely drug-resistant Gram-negative â€~superbugs'. Essays in Biochemistry, 2017, 61, 115-125.	4.7	71
134	Design and Evaluation of Novel Polymyxin Fluorescent Probes. Sensors, 2017, 17, 2598.	3.8	7
135	A Portrait of the Sialyl Glycan Receptor Specificity of the H10 Influenza Virus Hemagglutinin—A Picture of an Avian Virus on the Verge of Becoming a Pandemic?. Vaccines, 2017, 5, 51.	4.4	5
136	The thermodynamics of Pr55Gag-RNA interaction regulate the assembly of HIV. PLoS Pathogens, 2017, 13, e1006221.	4.7	33
137	Pharmacokinetics and relative bioavailability of an oral amoxicillin-apramycin combination in pigs. PLoS ONE, 2017, 12, e0176149.	2.5	5
138	Pharmacokinetics of levobupivacaine following infant spinal anesthesia. Paediatric Anaesthesia, 2016, 26, 575-581.	1.1	8
139	Global metabolic analyses identify key differences in metabolite levels between polymyxin-susceptible and polymyxin-resistant Acinetobacter baumannii. Scientific Reports, 2016, 6, 22287.	3.3	49
140	A Novel Chemical Biology Approach for Mapping of Polymyxin Lipopeptide Antibody Binding Epitopes. ACS Infectious Diseases, 2016, 2, 341-351.	3.8	16
141	The Plasma Protein Binding Proteome of Ertapenem: A Novel Compound-Centric Proteomic Approach for Elucidating Drug–Plasma Protein Binding Interactions. ACS Chemical Biology, 2016, 11, 3353-3364.	3.4	7
142	Near-Atomic Three-Dimensional Mapping for Site-Specific Chemistry of â€~Superbugs'. Nano Letters, 2016, 16, 7113-7120.	9.1	26
143	Transcriptomic Analysis of the Activity of a Novel Polymyxin against Staphylococcus aureus. MSphere, 2016, 1 , .	2.9	18
144	Deficiency in Outer Dense Fiber 1 Is a Marker and Potential Driver of Idiopathic Male Infertility. Molecular and Cellular Proteomics, 2016, 15, 3685-3693.	3.8	30

#	Article	IF	CITATIONS
145	Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?. International Journal of Antimicrobial Agents, 2016, 48, 592-597.	2.5	137
146	Development of HPLC and LC–MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1038, 57-62.	2.3	39
147	Polymyxins: a new hope in combating Gram-negative superbugs?. Future Medicinal Chemistry, 2016, 8, 1017-1025.	2.3	74
148	An "Unlikely―Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI. ACS Infectious Diseases, 2016, 2, 478-488.	3.8	80
149	Antibacterial low molecular weight cationic polymers: dissecting the contribution of hydrophobicity, chain length and charge to activity. RSC Advances, 2016, 6, 15469-15477.	3.6	58
150	Quantitation of Polymyxin–Lipopolysaccharide Interactions Using an Image-Based Fluorescent Probe. Journal of Pharmaceutical Sciences, 2016, 105, 1006-1010.	3.3	15
151	Anthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant Acinetobacter baumannii. Journal of Antibiotics, 2016, 69, 415-421.	2.0	27
152	Colistin-Induced Apoptosis of Neuroblastoma-2a Cells Involves the Generation of Reactive Oxygen Species, Mitochondrial Dysfunction, and Autophagy. Molecular Neurobiology, 2016, 53, 4685-4700.	4.0	43
153	Molecular Characterisation of the Haemagglutinin Glycan-Binding Specificity of Egg-Adapted Vaccine Strains of the Pandemic 2009 H1N1 Swine Influenza A Virus. Molecules, 2015, 20, 10415-10434.	3.8	6
154	Fatty Acid-binding Proteins 1 and 2 Differentially Modulate the Activation of Peroxisome Proliferator-activated Receptor \hat{l}_{\pm} in a Ligand-selective Manner. Journal of Biological Chemistry, 2015, 290, 13895-13906.	3.4	49
155	Synergistic killing of NDM-producing MDR <i>Klebsiella pneumoniae</i> by two †old†date oldê oldê oldê oldê oldê oldê oldê oldê	3.0	73
156	Cold adaptation generates mutations associated with the growth of influenza B vaccine viruses. Vaccine, 2015, 33, 5786-5793.	3.8	3
157	Lycopene Attenuates Colistin-Induced Nephrotoxicity in Mice via Activation of the Nrf2/HO-1 Pathway. Antimicrobial Agents and Chemotherapy, 2015, 59, 579-585.	3.2	105
158	Imaging the distribution of polymyxins in the kidney. Journal of Antimicrobial Chemotherapy, 2015, 70, 827-829.	3.0	54
159	Methotrexate-Conjugated PEGylated Dendrimers Show Differential Patterns of Deposition and Activity in Tumor-Burdened Lymph Nodes after Intravenous and Subcutaneous Administration in Rats. Molecular Pharmaceutics, 2015, 12, 432-443.	4.6	51
160	Significant Accumulation of Polymyxin in Single Renal Tubular Cells: A Medicinal Chemistry and Triple Correlative Microscopy Approach. Analytical Chemistry, 2015, 87, 1590-1595.	6.5	54
161	The carbohydrate-binding promiscuity of Euonymus europaeus lectin is predicted to involve a single binding site. Glycobiology, 2015, 25, 101-114.	2.5	27
162	Major Pathways of Polymyxin-Induced Apoptosis in Rat Kidney Proximal Tubular Cells. Antimicrobial Agents and Chemotherapy, 2015, 59, 2136-2143.	3.2	59

#	Article	IF	CITATIONS
163	Drug–drug plasma protein binding interactions of ivacaftor. Journal of Molecular Recognition, 2015, 28, 339-348.	2.1	34
164	Defining the Mechanisms by Which the Reactive Oxygen Species By-Product, 4-Hydroxynonenal, Affects Human Sperm Cell Function1. Biology of Reproduction, 2015, 92, 108.	2.7	76
165	Two Mechanisms of Killing of Pseudomonas aeruginosa by Tobramycin Assessed at Multiple Inocula via Mechanism-Based Modeling. Antimicrobial Agents and Chemotherapy, 2015, 59, 2315-2327.	3.2	76
166	Cellular Uptake and Localization of Polymyxins in Renal Tubular Cells Using Rationally Designed Fluorescent Probes. Antimicrobial Agents and Chemotherapy, 2015, 59, 7489-7496.	3.2	26
167	Antimicrobial Activity and Toxicity of the Major Lipopeptide Components of Polymyxin B and Colistin: Last-Line Antibiotics against Multidrug-Resistant Gram-Negative Bacteria. ACS Infectious Diseases, 2015, 1, 568-575.	3.8	124
168	Inhaled anti-infective chemotherapy for respiratory tract infections: Successes, challenges and the road ahead. Advanced Drug Delivery Reviews, 2015, 85, 65-82.	13.7	75
169	Analysis of Protein Thiol Changes Occurring During Rat Sperm Epididymal Maturation 1. Biology of Reproduction, 2015, 92, 11.	2.7	19
170	The RNA-Dependent-RNA Polymerase, an Emerging Antiviral Drug Target for the Hendra Virus. Current Drug Targets, 2014, 15, 103-113.	2.1	13
171	Nanoscale Focused Ion Beam Tomography of Single Bacterial Cells for Assessment of Antibiotic Effects. Microscopy and Microanalysis, 2014, 20, 537-547.	0.4	5
172	Measuring Polymyxin Uptake by Renal Tubular Cells: Is BODIPY-Polymyxin B an Appropriate Probe?. Antimicrobial Agents and Chemotherapy, 2014, 58, 6337-6338.	3.2	10
173	Colistin and Polymyxin B: Peas in a Pod, or Chalk and Cheese?. Clinical Infectious Diseases, 2014, 59, 88-94.	5.8	231
174	Probing the Penetration of Antimicrobial Polymyxin Lipopeptides into Gram-Negative Bacteria. Bioconjugate Chemistry, 2014, 25, 750-760.	3.6	103
175	<i>In situ</i> probing the interior of single bacterial cells at nanometer scale. Nanotechnology, 2014, 25, 415101.	2.6	8
176	A secondary mode of action of polymyxins against Gram-negative bacteria involves the inhibition of NADH-quinone oxidoreductase activity. Journal of Antibiotics, 2014, 67, 147-151.	2.0	156
177	Surface changes and polymyxin interactions with a resistant strain of <i>Klebsiella pneumoniae</i> Innate Immunity, 2014, 20, 350-363.	2.4	61
178	Teaching â€~Old' Polymyxins New Tricks: New-Generation Lipopeptides Targeting Gram-Negative â€~Superbugs'. ACS Chemical Biology, 2014, 9, 1172-1177.	3.4	139
179	Phosphopeptide Analysis of Rodent Epididymal Spermatozoa. Journal of Visualized Experiments, 2014, , .	0.3	14
180	The antigenic architecture of the hemagglutinin of influenza H5N1 viruses. Molecular Immunology, 2013, 56, 705-719.	2.2	47

#	Article	IF	Citations
181	Interaction of Phthalates and Phenoxy Acid Herbicide Environmental Pollutants with Intestinal Intracellular Lipid Binding Proteins. Chemical Research in Toxicology, 2013, 26, 1240-1250.	3.3	20
182	Pharmacokinetics of four different brands of colistimethate and formed colistin in rats. Journal of Antimicrobial Chemotherapy, 2013, 68, 2311-7.	3.0	58
183	Molecular basis for the increased polymyxin susceptibility of Klebsiella pneumoniae strains with under-acylated lipid A. Innate Immunity, 2013, 19, 265-277.	2.4	36
184	PK/PD models in antibacterial development. Current Opinion in Microbiology, 2013, 16, 573-579.	5.1	61
185	The specificity of the influenza B virus hemagglutinin receptor binding pocket: what does it bind to?. Journal of Molecular Recognition, 2013, 26, 439-449.	2.1	21
186	Head and flagella subcompartmental proteomic analysis of human spermatozoa. Proteomics, 2013, 13, 61-74.	2.2	115
187	Post-ejaculatory changes in the metabolic status of rat spermatozoa as measured by GC-MS. Metabolomics, 2013, 9, 708-721.	3.0	1
188	Pharmacology of polymyxins: new insights into an â€~old' class of antibiotics. Future Microbiology, 2013, 8, 711-724.	2.0	369
189	Reverse engineering the antigenic architecture of the haemagglutinin from influenza H5N1 clade 1 and 2.2 viruses with fine epitope mapping using monoclonal antibodies. Molecular Immunology, 2013, 53, 435-442.	2.2	9
190	Polymyxins and Analogues Bind to Ribosomal RNA and Interfere with Eukaryotic Translation in Vitro. ChemBioChem, 2013, 14, 2083-2086.	2.6	29
191	Interactions between Human Liver Fatty Acid Binding Protein and Peroxisome Proliferator Activated Receptor Selective Drugs. PPAR Research, 2013, 2013, 1-14.	2.4	61
192	Polymyxin B Induces Apoptosis in Kidney Proximal Tubular Cells. Antimicrobial Agents and Chemotherapy, 2013, 57, 4329-4335.	3.2	80
193	Molecular Characterization of Lipopolysaccharide Binding to Human < i > $\hat{l} \pm \langle l \rangle$ > 1-Acid Glycoprotein. Journal of Lipids, 2012, 2012, 1-15.	4.8	23
194	The Combination of Colistin and Doripenem Is Synergistic against Klebsiella pneumoniae at Multiple Inocula and Suppresses Colistin Resistance in an <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2012, 56, 5103-5112.	3.2	85
195	Analysis of Phosphopeptide Changes as Spermatozoa Acquire Functional Competence in the Epididymis Demonstrates Changes in the Post-translational Modification of Izumo 1. Journal of Proteome Research, 2012, 11, 5252-5264.	3.7	38
196	Drugâ€binding energetics of human αâ€1â€acid glycoprotein assessed by isothermal titration calorimetry and molecular docking simulations. Journal of Molecular Recognition, 2012, 25, 642-656.	2.1	24
197	Structure–activity relationships for the binding of polymyxins with human α-1-acid glycoprotein. Biochemical Pharmacology, 2012, 84, 278-291.	4.4	40
198	Characterization of the N-Methyltransferase Activities of the Multifunctional Polypeptide Cyclosporin Synthetase. Chemistry and Biology, 2011, 18, 464-475.	6.0	21

#	Article	IF	Citations
199	Design, synthesis, and evaluation of a new fluorescent probe for measuring polymyxin–lipopolysaccharide binding interactions. Analytical Biochemistry, 2011, 409, 273-283.	2.4	45
200	Self-Assembly Behavior of Colistin and Its Prodrug Colistin Methanesulfonate: Implications for Solution Stability and Solubilization. Journal of Physical Chemistry B, 2010, 114, 4836-4840.	2.6	63
201	Ligand-enhanced expression and in-cell assay of human peroxisome proliferator-activated receptor alpha ligand binding domain. Protein Expression and Purification, 2010, 70, 260-269.	1.3	7
202	Structureâ [^] Activity Relationships of Polymyxin Antibiotics. Journal of Medicinal Chemistry, 2010, 53, 1898-1916.	6.4	604
203	Developing an anion host for lipid A binding and antibacterial activity. Chemical Communications, 2010, 46, 3197.	4.1	35
204	Characterization of lipophilic drug binding to rat intestinal fatty acid binding protein. Molecular and Cellular Biochemistry, 2009, 326, 87-95.	3.1	18
205	Probing the Fibrate Binding Specificity of Rat Liver Fatty Acid Binding Protein. Journal of Medicinal Chemistry, 2009, 52, 5344-5355.	6.4	17
206	Thermodynamics of Lipophilic Drug Binding to Intestinal Fatty Acid Binding Protein and Permeation across Membranes. Molecular Pharmaceutics, 2009, 6, 557-570.	4.6	13
207	A protocol for the combined sub-fractionation and delipidation of lipid binding proteins using hydrophobic interaction chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 867, 238-246.	2.3	10
208	Characterization of the Drug Binding Specificity of Rat Liver Fatty Acid Binding Protein. Journal of Medicinal Chemistry, 2008, 51, 3755-3764.	6.4	63
209	Ni ²⁺ -Based Immobilized Metal Ion Affinity Chromatography of Lactose Operon Repressor Protein from <i>Escherichia Coli</i> Preparative Biochemistry and Biotechnology, 2008, 38, 422-441.	1.9	1
210	Structural and Biochemical Characterization of the Oxidoreductase NmDsbA3 from Neisseria meningitidis. Journal of Biological Chemistry, 2008, 283, 32452-32461.	3.4	23
211	Probing the Flexibility of the DsbA Oxidoreductase from Vibrio cholerae—a 15N - 1H Heteronuclear NMR Relaxation Analysis of Oxidized and Reduced Forms of DsbA. Journal of Molecular Biology, 2007, 371, 703-716.	4.2	21
212	Examination of the Role of Intestinal Fatty Acid-Binding Protein in Drug Absorption Using a Parallel Artificial Membrane Permeability Assay. Chemistry and Biology, 2007, 14, 453-465.	6.0	36
213	Generation of mutant leukaemia inhibitory factor (LIF)–IgG heavy chain fusion proteins as bivalent antagonists of LIF. Journal of Immunological Methods, 2007, 323, 1-10.	1.4	6
214	An improved purification procedure for cyclosporin synthetase. Protein Expression and Purification, 2006, 45, 275-287.	1.3	9
215	The Interaction of Lipophilic Drugs with Intestinal Fatty Acid-binding Protein. Journal of Biological Chemistry, 2005, 280, 17769-17776.	3.4	52
216	An improved method for the purification of rat liver-type fatty acid binding protein from Escherichia coli. Protein Expression and Purification, 2005, 44, 23-31.	1.3	13

TONY VELKOV

#	Article	IF	CITATION
217	Non-ribosomal peptide synthetases as technological platforms for the synthesis of highly modified peptide bioeffectors $\hat{a} \in \text{Cyclosporin}$ synthetase as a complex example. Biotechnology Annual Review, 2003, 9, 151-197.	2.1	22
218	Mapping and Molecular Modeling of S-Adenosyl-l-methionine Binding Sites in N-Methyltransferase Domains of the Multifunctional Polypeptide Cyclosporin Synthetase. Journal of Biological Chemistry, 2003, 278, 1137-1148.	3.4	22
219	Photoaffinity Labeling of the N-methyltransferase Domains of Cyclosporin Synthetase \hat{A}_{\P} . Photochemistry and Photobiology, 2003, 77, 129-137.	2.5	1
220	Photoaffinity Labeling of the N-methyltransferase Domains of Cyclosporin Synthetase¶. Photochemistry and Photobiology, 2003, 77, 129.	2.5	7